Skip to Content
by Leigh MacMillan | Posted on Thursday, Mar. 13, 2014 — 10:00 AM
Aberrant activation of Ras – a signaling protein that regulates cell growth and survival – plays a role in up to one-third of all human cancers. Turning off activated Ras is a promising therapeutic strategy, but Ras has been a challenging target because it lacks suitable binding “pockets.”
Stephen Fesik, Ph.D., Orrin H. Ingram, II Professor of Cancer Research, and colleagues now report an alternate approach: targeting proteins that regulate Ras, instead of Ras itself. They report in the March 4 Proceedings of the National Academy of Sciences the identification of small molecules that activate the Ras regulator, SOS (Son of Sevenless). SOS catalyzes the exchange of guanine nucleotides (GTP for GDP) on Ras, which is a required step for Ras activation. The newly identified small molecules bind to a unique pocket in the Ras:SOS:Ras complex. They increase the rate of guanine nucleotide exchange in vitro, but paradoxically disrupt downstream Ras signaling.
The compounds provide novel tools for studying acute Ras activation and represent a new approach for inhibiting Ras signaling.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to email@example.com
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research Aliquots, cancer, Cancer drug discovery, Department of Biochemistry, Department of Chemistry, Department of Pharmacology, Lustgarten Foundation, NCI, NIGMS, NIH, PNAS, ras, Reporter March 14 2014, Stephen Fesik, Vanderbilt Ingram Cancer Center
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: